DOCSLIB.ORG

Infection Prevention in Outpatient Oncology Settings CDC Offers Tools to Fight Back Against Infections Among Cancer Patients

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Infection Prevention in Outpatient Oncology Settings CDC Offers Tools to Fight Back Against Infections Among Cancer Patients Infection prevention in outpatient oncology settings CDC offers tools to fight back against infections among cancer patients. By aLICE y. GUh, MD, MPh, LiSa c. RICHARDSOn, MD, MPh, AND ANGeLa DUnBAR, BS espite advances in oncology care, infections remain a major www.preventcancerinfections.org 1-3 cause of morbidity and mortality among cancer patients. 1. What? PREPARE: Watch Out for Fever! You should take your temperature any time you blood cell count is likely to be the lowest since in that you are a cancer patient undergoing When? feel warm, flushed, chilled or not well. If you get a this is when you’re most at risk for infection chemotherapy. If you have a fever, you might temperature of 100.4°F (38°C) or higher for more (also called nadir). have an infection. This is a life threatening Several factors predispose cancer patients to developing infec- than one hour, or a one-time temperature of 101° • Keep a working thermometer in a convenient condition, and you should be seen in a short F or higher, call your doctor immediately, even if location and know how to use it. amount of time. it is the middle of the night. DO NOT wait until the • Keep your doctor’s phone numbers with you at office re-opens before you call. all times. Make sure you know what number to call when their office is open and closed. tions, including immunosuppression from their underlying You should also: • If you have to go to the emergency room, it's • Find out from your doctor when your white important that you tell the person checking you • If you develop a fever during your chemotherapy treatment it is a medical emergency. Why? cancer and chemotherapy treatment. Frequent contact with • Fever may be the only sign that you have an infection, and an infection during chemotherapy can be life threatening. 2. What? PREVENT: Clean Your Hands! Keeping your hands clean is important in Clean your hands: • Before and after treating a cut or wound or When? preventing infections. This should include you, all • Before, during, and after cooking food caring for your catheter, port or other access healthcare settings may expose them to other patients with members of your household, your doctors, • Before you eat device nurses and anyone that comes around you. Don't • After going to the bathroom be afraid to ask people to clean their hands. If • After changing diapers or helping a child to use soap and water are not available, it's o.k. to use the bathroom an alcohol-based hand sanitizer. • After blowing your nose, coughing, or sneezing transmissible infections. Patients with cancer often require the placement • After touching your pet or cleaning up after your pet D • After touching trash • Many diseases and conditions are spread by not cleaning your hands. Why? of long-term intravascular devices, such as implanted ports, to provide • Cleaning your hands is EXTREMELY important during chemotherapy treatment because your body can’t fight off infections like it used to. 3. What? PROTECT: Know the Signs and Symptoms of an Infection! During your chemotherapy treatment, your body • Nasal congestion Find out from your doctor when your white blood ease with chemotherapy infusion. However, these devices can provide When? will not be able to fight off infections like it used • Stiff neck cell count is likely to be the lowest since this is to. Call your doctor immediately if you notice any • Burning or pain with urination when you’re most at risk for infection. This usually of the following signs and symptoms of an • Unusual vaginal discharge or irritation occurs between 7 and 12 days after you finish infection: • Increased urination each chemotherapy dose—and will possibly last • Redness, soreness, or swelling in any area, up to one week. direct portal-of-entry for microorganisms to enter the bloodstream if • Fever (this is sometimes the only sign of including surgical wounds and ports an infection) • Diarrhea • Chills and sweats • Vomiting • Change in cough or new cough • Pain in the abdomen or rectum • Sore throat or new mouth sore • New onset of pain they are not appropriately disinfected prior to access. Thus, careful • Shortness of breath • Changes in skin, urination, or mental status • When your counts are low, take even the slightest sign or symptom of an infection as serious and call your doctor immediately. attention to proper infection prevention practices is essential to the care Why? • Infection during chemotherapy can be very serious, and can lead to hospitalization or death. Write the number(s) to call in Emergency Number Card of cancer patients to minimize their risks for infectious complications. an emergency here: 1. Treat a fever as an emergency. Doctor’s daytime number: 2. Call your doctor immediately if you develop a fever. ________________________________ 3. If you have to go to the emergency room, tell them right away that you are undergoing chemotherapy treatment. In recent decades, the vast majority of Furthermore, unlike acute care hospitals, Doctor’s after-hours number: Doctor’s daytime number:___________________________ Doctor’s after-hours number:_________________________ ________________________________ FEVER: TEMPERATURE OF 100.4°F (38°C) OR HIGHER FOR MORE THAN ONE HOUR OR A ONE-TIME TEMPERATURE OF 101° F OR HIGHER. oncology services have shifted from inpa- there is limited federal and state regula- www.preventcancerinfections.org tient to outpatient settings. Each year nearly tory oversight of many outpatient settings, Cut out the emergency number card. Fill in your doctor’s information. Carry this card with you at all times. 650,000 patients with cancer receive out- including outpatient oncology facilities. As 4 The Three Steps Brochure was created for cancer patient chemotherapy. However, not all a result, many outpatient facilities are not patients and caregivers to help increase awareness outpatient facilities maintain regular access routinely inspected for infection prevention about the importance of infection prevention. to infection prevention expertise or have practices. ImaGE COURTESY cdc/WWW.preventcancerinfections.ORG. dedicated infection prevention policies for Breaches in basic infection prevention prac- patient protection. tices have resulted in a number of outbreaks www.apic.org | 65 involving outpatient oncology settings. For storage and handling; and 5) safe handling example, in a Nebraska oncology clinic, and cleaning/disinfection of potentially syringe reuse to access saline bags shared contaminated equipment or surfaces in among multiple patients led to the trans- the patient environment. Procedures for mission of hepatitis C virus to at least 99 each component of Standard Precautions cancer patients, resulting in one of the are detailed in the BICAPP. For example, largest healthcare-associated outbreaks of as part of respiratory hygiene, triaging of viral hepatitis.5 Similar lapses in injection patients upon entry to the facility should safety (e.g., reusing single-dose vials on be performed, especially during periods multiple patients, storing prefilled saline of increased community respiratory virus flush syringes for later use) have also been activity, to prevent spread of respiratory implicated in outbreaks of bacterial blood- infections among clinic patients. Safe stream infections among cancer patients.6-8 injection practices that are relevant to Other identified lapses have included poor oncology facilities include appropriate hand hygiene, suboptimal disinfection of preparation and handling of saline and injection caps (e.g., needleless connectors) heparin syringes for flushing central lines. prior to accessing central lines, and inad- TRANSMISSION-BASED PRECAUTIONS. equate environmental conditions for che- Implementation of additional precautions, motherapy preparation. BICAPP can be used by any outpatient oncology facil- such as Contact Precautions, Droplet To help combat this public health chal- ity to standardize and improve infection prevention Precautions, and Airborne Precautions, may practices. ImaGE COURTESY the cdc. lenge, CDC launched its Preventing Infections be warranted in certain situations and should in Cancer Patients campaign in October assess adherence to recommended infection be applied based on a patient’s history and symptoms. 2011. This public health program offers prevention practices. healthcare providers, patients, and families a At Your Fingertips: A list of names of des- CENTRAL VENOUS CATHETERS. When accessing set of user-friendly resources designed to help ignated personnel and their specific roles a patient’s central line for infusions and reduce the risk of life-threatening infections and tasks and contact information that can blood draws, all facility staff should use during a cancer patient’s treatment. Each of be tailored to your facility is provided as an these tools is described in more detail in the appendix. following sections. SURVEILLANCE And REPORTING. Routine OUT OF SIGHT, OUT OF MIND... BASIC InfECTION CONTROL AND PREVENTION surveillance of infections (e.g., bloodstream NOT THIS TIME! FOR OUTPATIENT OncOLOGY SETTINGS (BICAPP) infections) and process measures related to The BICAPP (www.cdc.gov/hai/pdfs/guide- infection prevention practices (e.g., hand lines/basic-infection-control-prevention- hygiene) should be conducted for outbreak plan-2011.pdf) can be used by any outpatient detection and improvement of healthcare oncology facility to standardize and improve practices. Facility staff should also be aware infection prevention practices. The docu- of and adhere to local, state, and federal One of the most dangerous requirements for reportable diseases and side effects of chemotherapy ment is based on the CDC’s evidence-based cannot be seen? guidelines as well as relevant guidelines from outbreak reporting. That’s right, a low white blood cell count, professional societies and is tailored for quick At Your Fingertips: The BICAPP contains or neutropenia, puts cancer patients at a higher risk for getting an infection. implementation in outpatient oncology facil- an appendix where a facility can insert a list of An infection in people with cancer is an ities.
Load more

Recommended publications
  • Medical Oncology and Breast Cancer
    The Breast Center Smilow Cancer Hospital 20 York Street, North Pavilion New Haven, CT 06510 Phone: (203) 200-2328 Fax: (203) 200-2075 MEDICAL ONCOLOGY Treatment for breast cancer is multidisciplinary. The primary physicians with whom you may meet as part of your care are the medical oncologist, the breast surgeon, and often the radiation oncologist. A list of these specialty physicians will be provided to you. Each provider works with a team of caregivers to ensure that every patient receives high quality, personalized, breast cancer care. The medical oncologist specializes in “systemic therapy”, or medications that treat the whole body. For women with early stage breast cancer, systemic therapy is often recommended to provide the best opportunity to prevent breast cancer from returning. SYSTEMIC THERAPY Depending on the specific characteristics of your cancer, your medical oncologist may prescribe systemic therapy. Systemic therapy can be hormone pills, IV chemotherapy, antibody therapy (also called “immunotherapy”), and oral chemotherapy; sometimes patients receive more than one type of systemic therapy. Systemic therapy can happen before surgery (called “neoadjuvant therapy”) or after surgery (“adjuvant therapy”). If appropriate, your breast surgeon and medical oncologist will discuss the benefits of neoadjuvant and adjuvant therapy with you. As a National Comprehensive Cancer Network (NCCN) Member Institution, we are dedicated to following the treatment guidelines that have been shown to be most effective. We also have a variety of clinical trials that will help us find better ways to treat breast cancer. Your medical oncologist will recommend what treatment types and regimens are best for you. The information used to make these decisions include: the location of the cancer, the size of the cancer, the type of cancer, whether the cancer is invasive, the grade of the cancer (a measure of its aggressiveness), prognostic factors such as hormone receptors and HER2 status, and lymph node involvement.
    [Show full text]
  • Welcome to the Department of Oncology-Pathology
    Photo: H. Flank WELCOME TO THE DEPARTMENT OF ONCOLOGY-PATHOLOGY Photo: S. Ceder Photo: Erik Cronberg Photo: H. Flank Photo: E. H. Cheteh & S. Ceder t. Solna JohanOlof Wallins väg Wallins JohanOlof SKALA Solregnsvägen 0255075 100 125 m Solna kyrkväg Solnavägen Prostvägen 1 Prostvägen DEPARTMENT OF Fogdevreten ONCOLOGY-PATHOLOGY Prostvägen Granits väg Science for Life Laboratory We are a part of Karolinska Institutet, where we work with cancer research and offer Solna kyrkväg educational programs at undergraduate, Master and doctoral levels. Uniting more Tomtebodavägen than 30 research groups, the department´s broad focus on cancer combines basic, translational and clinical research, ranging from mechanisms of cancer development and biomarkers to development of new technologies for precision cancer medicine. Spårområde Karolinska vägen Thus, our goals are, based on fundamental discoveries, to identify and implement Nobels väg Tomtebodavägen cancer biomarkers supporting early diagnosis and improved personalized therapy, Widerströmska building and to drive drug discovery via innovative clinical trials. Further, we engage in edu-Tomtebodavägen cation of next generation scientist and healthcare professionals in these areas.P Our research teams are mainly located at two research buildings, Bioclinicum and Science for Life Laboratories (SciLifeLab), Solna, and at hospital buildings including Pathology unit and New Karolinska Hospital (NKS), Stockholm. In addition, few Scheeles väg Theorells väg research groups form satellites in Södersjukhuset, Karolinska hospital in Huddinge 3 and at Cancercentrum Karolinska, Solna. Karolinska vägen Scheeles väg Retzius väg Nobels väg Biomedicum Solnavägen Science for Life laboratories Individual research groups are part of both the department of Oncology-Pathology and Tomtebodavägen the SciLifeLabs national infrastructure.
    [Show full text]
  • Covid Management of Liquid Oncology Patients
    CELLICONE VALLEY ‘21: THE FUTURE OF CELL AND GENE THERAPIES COVID MANAGEMENT OF LIQUID ONCOLOGY PATIENTS Abbey Walsh, MSN, RN, OCN – Clinical Practice Lead, Outpatient Infusion Therapy Angela Rubin, BSN, RN, OCN – Clinical Nurse III, Outpatient Infusion Therapy May 6th, 2021 Disclosures: ‣ Both presenters have disclosed no conflicts of interests related to this topic. 2 Objectives: ‣ Describe the evolution of COVID management for oncology patients being treated in ambulatory care. ‣ Identity the role of EUA monoclonal antibody treatments for COVID + oncology patients. ‣ Review COVID clearance strategies: past and present. ‣ Explain Penn Medicine's role in COVID vaccinations for oncology patients. ‣ Explain COVID – 19 special care considerations for oncology patients: • Emergency Management • Neutropenic Fevers/Infectious Work-ups • Nurse-Driven Initiatives • Cancer Center Initiatives to enhance patient safety and infection risk 3 Evolution of COVID Management for Oncology Patients in Ambulatory Care Late March – Early April 2020: COVID Testing Strategies “COLD” Testing “HOT” Testing • Assume these patients are COVID Negative. • Actively COVID + or suspicious for COVID/PUI • No need for escort in and out of the building (Patient under investigation) • Maintain Droplet Precautions: • Require RN/CNA escort in and out of building. • Enhanced PPE for COVID swab only • Enhanced precautions: • Patients who are asymptomatic but require • (Enhanced) Droplet + Contact COVID testing: • Upgrade to N95 during aerosolizing • Pre-admission procedures • Pre-procedural • (PUIs)-COVID testing indicated because of: New Symptoms, Recent Travel, Recent known exposure to Covid + individual • Examples: Port placement, starting radiation treatment, CarT therapy, Stem • Example: Liquid oncology patient arrives Cell/Bone Marrow Transplant patients for chemo treatment, but reports new cough and fevers up to 101 over the last • Exlcusion: pre-treatment outpatient anti- few days.
    [Show full text]
  • Oncology 101 Dictionary
    ONCOLOGY 101 DICTIONARY ACUTE: Symptoms or signs that begin and worsen quickly; not chronic. Example: James experienced acute vomiting after receiving his cancer treatments. ADENOCARCINOMA: Cancer that begins in glandular (secretory) cells. Glandular cells are found in tissue that lines certain internal organs and makes and releases substances in the body, such as mucus, digestive juices, or other fluids. Most cancers of the breast, pancreas, lung, prostate, and colon are adenocarcinomas. Example: The vast majority of rectal cancers are adenocarcinomas. ADENOMA: A tumor that is not cancer. It starts in gland-like cells of the epithelial tissue (thin layer of tissue that covers organs, glands, and other structures within the body). Example: Liver adenomas are rare but can be a cause of abdominal pain. ADJUVANT: Additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back. Adjuvant therapy may include chemotherapy, radiation therapy, hormone therapy, targeted therapy, or biological therapy. Example: The decision to use adjuvant therapy often depends on cancer staging at diagnosis and risk factors of recurrence. BENIGN: Not cancerous. Benign tumors may grow larger but do not spread to other parts of the body. Also called nonmalignant. Example: Mary was relieved when her doctor said the mole on her skin was benign and did not require any further intervention. BIOMARKER TESTING: A group of tests that may be ordered to look for genetic alterations for which there are specific therapies available. The test results may identify certain cancer cells that can be treated with targeted therapies. May also be referred to as genetic testing, molecular testing, molecular profiling, or mutation testing.
    [Show full text]
  • Interventional Radiology in the Diagnosis and Treatment of Solid Tumors
    THE ROLE OF INTERVENTIONAL RADIOLOGY IN THE DIAGNOSIS AND TREATMENT OF SOLID TUMORS Victoria L. Anderson, MSN, CRNP, FAANP OBJECTIVES •Using Case Studies and Imaging examples: 1) Discuss the role interventional (IR) procedures to aid in diagnosing malignancy 2) Current and emerging techniques employed in IR to cure and palliate solid tumor malignancies will be explored Within 1 and 2 will be a discussion of research in the field of IR Q+A NIH Center for Interventional Oncology WHAT IS INTERVENTIONAL RADIOLOGY? • Considered once a subspecialty of Diagnostic Radiology • Now its own discipline, it serves to offer minimally invasive procedures using state-of- the-art modern medical advances that often replace open surgery (Society of Interventional Radiology) NIH Center for Interventional Oncology CHARLES T. DOTTER M.D. (1920-1985) • Father of Interventional Radiologist • Pioneer in the Field of Minimally Invasive Procedures (Catheterization) • Developed Continuous X-Ray Angio- Cardiography • Performed First If a plumber can do it to pipes, we can do it to blood vessels.” Angioplasty (PTCA) Charles T. Dotter M.D. Procedure in 1964. • Treated the first THE ROOTS OF patient with catheter assisted vascular INTERVENTIONAL dilation RADIOLOGY NIH Center for Interventional Oncology THE “DO NOT FIX” CONSULT THE DO NOT FIX PATIENT SCALES MOUNT HOOD WITH DR. DOTTER 1965 NIH Center for Interventional Oncology •FIRST EMBOLIZATION FOR GI BLEEDING •ALLIANCE WITH •FIRST BALLOON BILL COOK •HIGH SPEED PERIPHERAL DEVELOPED RADIOGRAPHY ANGIOPLASTY-- NUMEROUS
    [Show full text]
  • Unique Issues Facing Primary Care Providers
    What is Primary Care Oncology? Unique Issues Facing Primary Care Providers Amy E. Shaw, MD Medical Director, Cancer Survivorship and Primary Care Oncology Annadel Medical Group Santa Rosa, California January 16, 2016 The Breast Cancer Journey: Together with Primary Care Bellingham, Washington This CME presentation was developed independent of any commercial influences Trends in Incidence Rates for Selected Cancers, United States, 1975 - 2011. CA: A Cancer Journal for Clinicians Volume 65, Issue 1, JAN 2015 Trends in Death Rates Overall and for Selected Sites, United States, 1930 - 2011 CA: A Cancer Journal for Clinicians Volume 65, Issue 1, pages 5-29, 5 JAN 2015 Trend in 5-Year Survival 1971-2005 Source: The State of Cancer Care in America: 2014; ASCO * Due to earlier detection and more effective treatments. 2005: Cancer Survivor care lacking • 10 million cancer survivors • Institute of Medicine report: • From Cancer Patient to Cancer Survivor: Lost in Transition • Identified a discontinuity (“gap”) in care between acute cancer care and primary care • Proposed solutions, set goals 1. Surveillance and screening • Cancer recurrence, new primary cancers, complications of cancer treatment 2. Prevention of late effects of cancer treatment or second cancers 3. Promotion of Healthy Lifestyle • Risk reduction counseling and interventions 4. Coordination of care and communication • Continuity of care between specialists and primary care physicians 5. Treatment • Of ongoing or late-onset physical and psychological symptoms of cancer or cancer therapies (NOT TREATMENT OF CANCER) Institute of Medicine. From Cancer Patient to Cancer Survivor: Lost in Transition. 2005 2015: 10 years later How are we doing? 2015: CDC Report • Now 15 million cancer survivors • 24 million cancer survivors by 2025 • Survivorship Programs in many hospitals • Medical care of survivors still lacking • Example: 60% of breast cancer patients report cognitive impairment after cancer treatment.
    [Show full text]
  • ONCOLOGY PATHOLOGY™ Towards Harmonization of Pathology and Oncology Standards
    This activity is approved Register Now! for AMA PRA Category 1 Credit™. nd 2 Annual International Congress on ONCOLOGY PATHOLOGY™ Towards Harmonization of Pathology and Oncology Standards Crowne Plaza® Times Square Manhattan Saturday, June 23, 2018 • 1605 Broadway, New York, NY 10019 Program Co-Chairs Alain Borczuk, MD Balazs Halmos, MD Professor of Pathology and Laboratory Professor of Clinical Medicine Medicine Director, Thoracic/Head & Neck Oncology Vice Chairman for Anatomic Pathology Director, Clinical Cancer Genomics Department of Pathology and Albert Einstein College of Medicine/ Laboratory Medicine Montefiore Medical Center Weill Cornell Medicine Bronx, NY New York, NY Meet the Experts and Learn: • The expanded role of liquid biopsies in cancer management • Clinical updates and new considerations for microsatellite stability testing • The latest on emerging pan-tumor targets, including tumor fusions • A new approach to prognostic staging in breast cancer • Multidisciplinary approaches to bridge the gap between pathology and oncology To register visit gotoper.com/go/ICOP18BRO Meeting Overview The 2nd Annual International Congress on Oncology Pathology™: Towards Harmonization of Pathology and Oncology Standards will provide the latest information on key topics in pathology that can readily be applied to clinical practice in a variety of settings. This congress will bring together oncologists and pathologists to facilitate awareness of recent advancements in the field of cancer pathology and enhance multidisciplinary collaboration.
    [Show full text]
  • Advances in Radiation Oncology
    Advances in Radiation Oncology COVID-19 infection prevention and control practices in Wuhan radiotherapy --Manuscript Draft-- Manuscript Number: ADVANCESRADONC-D-20-00120R1 Article Type: Letter to the Editor Section/Category: Clinical Investigation - Other Corresponding Author: Steven J Chmura, MD, PhD University of Chicago Chicago, IL United States First Author: Cheng Chen, M.Sc. Order of Authors: Cheng Chen, M.Sc. Zhengkai Liao, M.D., Ph.D. Steven J Chmura, MD, PhD Ralph R. Weichselbaum, M.D. Abstract: Radiotherapy outcomes depend on the presence of skilled technical staff. There is concern as to how to protect staff and patients when receiving daily radiotherapy. In Wuhan, during the COVID-19 outbreak from January 28 2020 to March 10 2020, 153 patients with 1,752 visits underwent radiotherapy in Zhongnan Hospital. Of 39 staff personnel none as yet have developed symptoms and / or molecular indication of COVID-19 infection, including SARS-Cov-2 Real-time RT-PCR, IgM, and IgG. To achieve these results, we implemented the measures outlined below (Figure 1). Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation Title Page (WITH Author Details) COVID-19 infection prevention and control practices in Wuhan radiotherapy Cheng Chen, M.Sc.1, Zhengkai Liao, M.D., Ph.D.1*, Steven J. Chmura, M.D., Ph.D.2, Ralph R. Weichselbaum, M.D.2 1 Department of Radiation and Medical Oncology, and Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430070, China 2 Department of Radiation and Cellular Oncology, and the Ludwig Center for Metastasis Research, University of Chicago Medicine, Chicago IL 60637 * Correspondence: Zhengkai Liao, M.D., Ph.D.
    [Show full text]
  • Analysis of Body Mass Index and Mortality in Patients with Colorectal Cancer Using Causal Diagrams
    Research JAMA Oncology | Original Investigation Analysis of Body Mass Index and Mortality in Patients With Colorectal Cancer Using Causal Diagrams Candyce H. Kroenke, ScD; Romain Neugebauer, PhD; Jeffrey Meyerhardt, MD; Carla M. Prado, PhD; Erin Weltzien, BA; Marilyn L. Kwan, PhD; Jingjie Xiao, MS; Bette J. Caan, DrPH Editorial page 1127 IMPORTANCE Physicians and investigators have sought to determine the relationship Supplemental content between body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]) and colorectal cancer (CRC) outcomes, but methodologic limitations including sampling selection bias, reverse causality, and collider bias have prevented the ability to draw definitive conclusions. OBJECTIVE To evaluate the association of BMI at the time of, and following, colorectal cancer (CRC) diagnosis with mortality in a complete population using causal diagrams. DESIGN, SETTING, AND PARTICIPANTS This retrospective observational study with prospectively collected data included a cohort of 3408 men and women, ages 18 to 80 years, from the Kaiser Permanente Northern California population, who were diagnosed with stage I to III CRC between 2006 and 2011 and who also had surgery. EXPOSURES Body mass index at diagnosis and 15 months following diagnosis. MAIN OUTCOMES AND MEASURES Hazard ratios (HRs) for all-cause mortality and CRC-specific mortality compared with normal-weight patients, adjusted for sociodemographics, disease severity, treatment, and prediagnosis BMI. RESULTS This study investigated a cohort of 3408 men and women ages 18 to 80 years diagnosed with stage I to III CRC between 2006 and 2011 who also had surgery. At-diagnosis BMI was associated with all-cause mortality in a nonlinear fashion, with patients who were underweight (BMI <18.5; HR, 2.65; 95% CI, 1.63-4.31) and patients who were class II or III obese (BMI Ն35; HR, 1.33; 95% CI, 0.89-1.98) exhibiting elevated mortality risks, compared with patients who were low-normal weight (BMI 18.5 to <23).
    [Show full text]
  • UCLA Introduces Triage Protocol for Patients with Metastatic Brain Tumors
    UCLA introduces triage protocol for patients with metastatic brain tumors Laser ablation targets cancer cells in brain with focused heat therapy Laser ablation surgery is the newest high-tech tool in the UCLA Brain Tumor Program’s arsenal for treating metastatic brain tumors. This minimally invasive treatment — used for decades to treat other conditions — employs laser energy to heat and destroy cancerous cells from the inside out while sparing healthy tissue. Guided by real-time magnetic resonance imaging (MRI), the neurosurgeon makes a tiny incision (about 4 millimeters) and a hole in the skull about the diameter of a chopstick. A thin, fiber-optic laser probe follows that pathway Neurosurgeons and radiation oncologists in the UCLA Brain Tumor Program to the tumor location. Real-time routinely collaborate to provide the latest in high-tech care for patients with MRI allows the neurosurgeon to metastatic brain tumors, including minimally invasive surgery, whole-brain track the area being heated. The radiation, fractionated stereotactic radiation, stereotactic radiosurgery and extremely precise technique works laser-ablation therapy. well on tumors that are small, inoperable or have failed other Now, these experts have created a single point of contact for all patients with therapies. With this minimally metastatic brain tumors to provide easy and rapid access to optimal treatment invasive approach, patients typically solutions. In this enhanced, dedicated service, an internal triage staff immediately recover faster than with open surgery and are discharged from evaluates the patient’s needs and offers a same-day or next-day appointment (or the hospital the next day. another time convenient for the patient) with a neurosurgeon, radiation oncologist or both.
    [Show full text]
  • HENRY BREM, M.D. Harvey Cushing Professor Professor Of
    HENRY BREM, M.D. Harvey Cushing Professor Professor of Neurosurgery, Ophthalmology, Oncology and Biomedical Engineering Director, Department of Neurosurgery Director, Hunterian Neurosurgical Research Laboratory Director, Neurosurgery Pain Research Institute at Johns Hopkins Johns Hopkins University School of Medicine Henry Brem has developed new tools and techniques that have changed the field of neurosurgery. Brem carried out the pivotal clinical study that introduced navigational imaging into the neurosurgical suite. His work led to the FDA's approval of the first image guidance computer system for intraoperative localization of tumors. Furthermore, he has changed the surgical armamentarium against brain tumors by inventing and developing Gliadel® wafers to intraoperatively deliver chemotherapy to brain tumors. His work has shown that surgeons can deliver potent therapies directly at the tumor site. Henry Brem is the Harvey Cushing Professor of Neurosurgery, Oncology, Ophthalmology, and Biomedical Engineering, and Director of Neurosurgery at Johns Hopkins. He received his undergraduate degree from New York University, his medical degree from Harvard, and trained in neurosurgery at Columbia. He has built one of the largest brain tumor research and treatment centers in the world. He reinstituted the Hunterian Neurosurgery Laboratory (originally founded by Cushing) and has trained numerous researchers who have changed the fields of intraoperative imaging, angiogenesis, immunotherapy, and controlled release polymers for drug delivery to the brain. Brem has changed the surgical treatment of brain tumors by introducing new approaches for targeted therapy. He developed new classes of polymers for drug delivery that are custom synthesized for the agent being developed. The polyanhydrides, which are the first new treatments for brain tumors that the FDA has approved in 23 years, have been shown in his laboratory to be biocompatible and potent.
    [Show full text]
  • Ucla Brain Tumor Center
    UCLA BRAIN TUMOR CENTER UCLA is home to one of the world’s leading centers for the research, diagnosis and treatment of brain tumors. Since 1991, we have cared for nearly 5,000 people with brain tumors. Among the top five programs in the country, the UCLA Brain Tumor Center draws patients from all over the world. We take an aggressive treatment approach, caring for patients with more than 30 different types of brain tumors. We offer personalized precision therapies that rely on the most advanced imaging and surgical tools, the latest radiotherapy and chemotherapy agents, and the most promising and innovative clinical trials. Our expertise is showcased throughout every aspect of our program. We are a national leader in immunotherapy. We pioneer advanced techniques such as awake craniotomy brain mapping. We harness new technology like virtual reality for surgical planning, and integrate fMRI and next-generation imaging modalities into our program. Combined with our utmost compassion for patients, the UCLA Brain Tumor Center offers care that is second to none. Recognition for World-Class At the Forefront of Brain Tumor Brain Tumor Care Clinical Research • UCLA is ranked among the top eight medical centers in Using an integrated approach to research and clinical the nation for neurology and neurosurgery, and among care, we consider every patient for possible participation the top five for cancer programs by U.S. News and World in clinical trials to help them achieve the best possible Report, achieving excellent scores in survival, patient clinical outcome. As one of the first programs in the safety, patient volume, nurse-to-patient ratios, advanced country with a dedicated brain tumor bio/data repository, technologies, and key patient services.
    [Show full text]